Do you have Parkinson’s Disease and depression? Join Our Clinical Trial.


Yale University is evaluating the safety and effectiveness of an FDA-approved antidepressant called ketamine for individuals with Parkinson’s disease (PD). 

  • We believe that ketamine could reduce depression and possibly target other symptoms of PD. 
  • Participants will be randomly assigned to receive either the study drug (ketamine) or placebo (doesn’t have an active component) twice a week for 3 weeks.
  • You will also have the option to take part in brain imaging before and after the treatment. 
  • You will be reimbursed up to $2000 for your time. 

You may be eligible to join the study if you: 

  • Are between 40-80 years old 
  • Have a diagnosis of PD
  • Have symptoms of depression  

Contact us to find out more!

E-mail: Call or Text: (475) 287-9521

Leave a Reply

Your email address will not be published. Required fields are marked *

copyright 2021